research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
Genetic studies of Xanthoria parietina have revealed significant differentiation among populations, with genetic variation structured by both geographic distance and substrate type. Populations growing on tree bark show higher genetic diversity than those on rock surfaces, though there is no evidence of restricted gene flow between populations on the same substrate type, even when separated by distances of up to 25 km (16 mi). Despite these genetic differences, no corresponding morphological or chemical variation has been observed. At fine spatial scales, X. parietina exhibits high genetic diversity within local populations, with most genetic variation (up to 90%) occurring within rather than between populations. Studies using IGS and ITS (genetic markers used to assess variation) reveal significant diversity even among closely located individuals. Research from Storfosna island, Norway, suggests long-term local adaptation to bark or rock habitats has led to habitat-specific genetic variants, shaping the overall population structure. While local populations may have limited genetic diversity, populations from different geographic regions show significant genetic differentiation. For example, Antarctic populations of Rusavskia elegans from sites just 5–15 km (3.1–9.3 mi) apart differed by one nucleotide. In contrast, those separated by 660 km (410 mi) showed a 14.2% divergence in their DNA sequences.
== External links == Clinical trial number NCT02666664 for "Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)" at ClinicalTrials.gov Clinical trial number NCT02988115 for "Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant (CLEAR Serenity)" at ClinicalTrials.gov Clinical trial number NCT02991118 for "Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk (CLEAR Wisdom)" at ClinicalTrials.gov
=== Avionics, military and government === In 1929 Vincent Bendix branched out into aeronautics and restructured the company as "Bendix Aviation" to reflect the new product lines. Bendix Aviation was founded as a holding company for the assets of Delco Aviation Corporation, Eclipse Machine Company, Stromberg Carburetor Company, and other aircraft accessory manufacturers. Bendix supplied aircraft manufacturers with hydraulic systems, for braking and flap activation, and introduced the pressure carburetor. It made a wide variety of electrical and electronic instruments for aircraft. From 1931, it sponsored the Bendix Trophy, a transcontinental U.S. point-to-point race intended to encourage the development of commercial aircraft. During and after World War II Bendix made radar equipment of various types. Bendix ranked 17th among United States corporations in the value of wartime production contracts. Bendix aviation masks and gauges were modified and tested for use in diving and hyperbaric applications. In the 1950s, Bendix and its successors managed United States Atomic Energy Commission facilities in Kansas City, Missouri and Albuquerque, New Mexico. These facilities procured non-nuclear components for nuclear weapons.
Sources: en.wikipedia.org
The 2001 Copa América, hosted by Colombia, was nearly lost to the country's security situation. CONMEBOL held three meetings on the matter: on 28 June 2001 the tournament was moved out of Colombia, on 30 June it was returned but postponed to 2002, and on 5 July the original schedule was confirmed. Canada, one of two invited guests, withdrew on 6 July and Argentina on 10 July, the day before the opening match; Costa Rica and Honduras were invited in their place. Honduras arrived with a hastily assembled squad and went on to reach the semi-finals. Colombia won Group A with maximum points, all three matches played at the Estadio Metropolitano Roberto Meléndez in Barranquilla: Venezuela were beaten 2–0 through Freddy Grisales and a Víctor Aristizábal penalty, Ecuador 1–0 through Aristizábal, and Chile 2–0 through an Aristizábal penalty and a 90th-minute goal from Iván Arriaga. Peru were beaten 3–0 in the quarter-finals at Armenia, Aristizábal scoring twice, and Honduras — who had eliminated Brazil in the previous round — were beaten 2–0 in the semi-final at the Estadio Palogrande in Manizales, Bedoya scoring inside six minutes and Aristizábal adding the second. In the final at the Estadio El Campín in Bogotá on 29 July, before 47,000 spectators, Iván Córdoba headed in the only goal in the 65th minute to beat Mexico 1–0 and win Colombia's first major trophy. Colombia won the competition without conceding a goal, keeping six clean sheets in six matches and scoring eleven, the highest total of the tournament.
=== Benzene exposure limits === The United States Environmental Protection Agency has set a maximum contaminant level for benzene in drinking water at 0.005 mg/L (5 ppb), as promulgated via the US National Primary Drinking Water Regulations. This regulation is based on preventing benzene leukemogenesis. The maximum contaminant level goal (MCLG), a nonenforceable health goal that would allow an adequate margin of safety for the prevention of adverse effects, is zero benzene concentration in drinking water. The EPA requires that spills or accidental releases into the environment of 10 pounds (4.5 kg) or more of benzene be reported. The US Occupational Safety and Health Administration (OSHA) has set a permissible exposure limit of 1 part of benzene per million parts of air (1 ppm) in the workplace during an 8-hour workday, 40-hour workweek. The short term exposure limit for airborne benzene is 5 ppm for 15 minutes. These legal limits were based on studies demonstrating compelling evidence of health risk to workers exposed to benzene. The risk from exposure to 1 ppm for a working lifetime has been estimated as 5 excess leukemia deaths per 1,000 employees exposed. (This estimate assumes no threshold for benzene's carcinogenic effects.) OSHA has also established an action level of 0.5 ppm to encourage even lower exposures in the workplace. The US National Institute for Occupational Safety and Health (NIOSH) revised the Immediately Dangerous to Life and Health (IDLH) concentration for benzene to 500 ppm.
Yonath was a member of the United States National Academy of Sciences; the American Academy of Arts and Sciences; the Israel Academy of Sciences and Humanities; the European Academy of Sciences and Art and the European Molecular Biology Organization. On 18 October 2014, Yonath was named an ordinary member of the Pontifical Academy of Sciences by Pope Francis. Her awards and honors included the following:
Additional regulation over the housing market would have been beneficial, according to former Federal Reserve chairman Alan Greenspan. Bush, meanwhile, proposed a financial rescue plan to buy back a large portion of the U.S. mortgage market. Vince Reinhardt, a former Federal Reserve economist now at the American Enterprise Institute, said "it would have helped for the Bush administration to empower the folks at Treasury and the Federal Reserve and the comptroller of the currency and the FDIC to look at these issues more closely", and additionally, that it would have helped "for Congress to have held hearings".
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.